^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
livmoniplimab (ABBV-151)
i
Other names: ABBV-151, ARGX 115, ARGX-115, ABBV 151
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie, argenx
Drug class:
TGF-β1 inhibitor, LRRC32 inhibitor
Related drugs:
2d
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
P2, N=150, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Metastases
|
gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
2ms
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) (clinicaltrials.gov)
P2, N=150, Not yet recruiting, AbbVie
New P2 trial
|
gemcitabine • paclitaxel • docetaxel • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
3ms
LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=130, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
Enrollment closed • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
sorafenib • Lenvima (lenvatinib) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
3ms
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P1, N=20, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
6ms
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P1, N=20, Not yet recruiting, AbbVie
New P1 trial • Adverse events • Combination therapy • Checkpoint inhibition • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
8ms
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=362, Recruiting, AbbVie | Trial primary completion date: Feb 2026 --> Jun 2027
Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
9ms
LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2/3, N=840, Recruiting, AbbVie | Not yet recruiting --> Recruiting
Enrollment open • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
10ms
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=337, Recruiting, AbbVie | Trial completion date: Feb 2026 --> Jun 2027
Trial completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
10ms
LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2/3, N=840, Not yet recruiting, AbbVie
New P2/3 trial • Adverse events • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3
Enrollment open • Phase classification • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=660, Not yet recruiting, AbbVie
New P2 trial • Adverse events • Combination therapy • Metastases
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
1year
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=337, Recruiting, AbbVie | Trial completion date: Apr 2024 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
over3years
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=260, Recruiting, AbbVie | N=184 --> 260 | Trial primary completion date: Jul 2022 --> Apr 2023
Clinical • Enrollment change • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
over3years
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=184, Recruiting, AbbVie | Trial completion date: Jul 2022 --> Apr 2023
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
over4years
[VIRTUAL] Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours (ESMO 2020)
Funding: AbbVie Inc. Clinical trial identification: NCT03821935.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
Share via
